2024
CCR2+ monocytes are dispensable to resolve acute pulmonary Pseudomonas aeruginosa infections in WT and cystic fibrosis mice
Öz H, Braga C, Gudneppanavar R, Di Pietro C, Huang P, Zhang P, Krause D, Egan M, Murray T, Bruscia E. CCR2+ monocytes are dispensable to resolve acute pulmonary Pseudomonas aeruginosa infections in WT and cystic fibrosis mice. Journal Of Leukocyte Biology 2024, 117: qiae218. PMID: 39365279, PMCID: PMC11953069, DOI: 10.1093/jleuko/qiae218.Peer-Reviewed Original ResearchLung tissue damageCystic fibrosisTissue damageMonocyte recruitmentImmune responsePulmonary Pseudomonas aeruginosa infectionHyper-inflammatory immune responseCystic fibrosis micePropagate tissue damagePseudomonas aeruginosaLungs of patientsChronic neutrophilic inflammationImmunological response to infectionHost immune responseMonocyte-derived macrophagesTarget monocyte recruitmentSite of injuryResponse to infectionCFTR modulatorsPA infectionChronic inflammatory disease conditionsReduced bactericidal activityAdjunctive therapyClinical outcomesEradicate infection
2020
584. Ventricular assist device infections with Pseudomonas aeruginosa
Roberts S, Nam H, Kumar R, Zembower T, Qi C, Malczynski M, Rich J, Pawale A, Harap R, Stosor V. 584. Ventricular assist device infections with Pseudomonas aeruginosa. Open Forum Infectious Diseases 2020, 7: s356-s356. PMCID: PMC7776381, DOI: 10.1093/ofid/ofaa439.778.Peer-Reviewed Original ResearchDriveline exit siteVAD-specific infectionsVAD infectionsPA infectionVentricular assist device infectionVentricular assist device recipientsPseudomonas aeruginosaSuccessful heart transplantationInfection prevention strategiesNorthwestern Memorial HospitalMultiple antibiotic classesWarrants further studyAntibiotic coursesFQ monotherapyISHLT guidelinesProlonged antibioticsHeart transplantationSurgical debridementVAD implantationCerebrovascular accidentInitial diagnosisMedian timeDevice implantationDevice recipientsAntibiotic treatment
2017
Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa
Dickhaus F, Abu Hasan M, Tremblay E, Klinker K, Rand K, Beal S. Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. Journal Of Microbiology And Infectious Diseases 2017, 07: 178-185. DOI: 10.5799/jmid.368802.Peer-Reviewed Original ResearchMucoid PA infectionUF Health Shands HospitalCystic fibrosis patientsPA infectionFibrosis patientsTobramycin treatmentShands HospitalRetrospective chart review studyAdult cystic fibrosis patientsFlorida CollegeChart review studyTertiary care institutionPseudomonas aeruginosaDifferent antimicrobial regimensDepartment of PediatricsDepartment of PathologyNon-mucoid Pseudomonas aeruginosaAllergy divisionPediatric PulmonaryStudy patientsPulmonary functionAntimicrobial regimensMore hospitalizationsTobramycin therapyPA patients
2011
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
Mayer‐Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch‐Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, Investigators F. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonology 2011, 47: 125-134. PMID: 21830317, PMCID: PMC3214247, DOI: 10.1002/ppul.21525.Peer-Reviewed Original ResearchConceptsExacerbation riskInitial eradicationCystic fibrosisPseudomonas aeruginosa acquisitionInitial antibiotic treatmentPositive respiratory culturesPA recurrenceProportional hazards modelSymptom-based definitionEPIC trialPulmonary exacerbationsAntibiotic therapyTreatment failureClinical benefitPA infectionRespiratory culturesSubsequent exacerbationAntibiotic treatmentEarly eradicationHigh riskNegative culturesExacerbationHazards modelSignificant predictorsTrials
2009
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, Group E. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials 2009, 30: 256-268. PMID: 19470318, PMCID: PMC2783320, DOI: 10.1016/j.cct.2009.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinCohort StudiesCystic FibrosisDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInfantLongitudinal StudiesMalePseudomonas aeruginosaPseudomonas InfectionsRisk FactorsTobramycinTreatment OutcomeConceptsEarly Pa infectionYoung CF patientsRespiratory culturesRisk factorsCystic fibrosisCohort studyPA infectionClinical trialsObservational studyCF patientsEarly CF lung diseaseProgressive obstructive pulmonary diseaseProportion of patientsClinical efficacy dataObstructive pulmonary diseasePositive respiratory culturesPatients ages 1Longitudinal cohort studyCF lung diseaseChronic endobronchial infectionInfection control programPa acquisitionPA-negative patientsOral ciprofloxacinOral placebo
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply